Eeyarestatin I-E isomer | 1310099-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: Eeyarestatin I-E isomer
• 英文别名: 2-[3-(4-chlorophenyl)-4-[(4-chlorophenyl)carbamoyl-hydroxyamino]-5,5-dimethyl-2-oxoimidazolidin-1-yl]-N-[(Z)-[(E)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]acetamide
• CAS: 1310099-63-8
• 化学式: C27H25Cl2N7O7
• 分子量: 630.4
• InChiKey: JTUXTPWYZXWOIB-LBSHJFKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  177
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• NEW TREATMENT FOR NEURODEGENERATIVE DISEASES
  申请人：Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research

  公开号：EP2776022A1

  公开（公告）日：2014-09-17
• Treatment for neurodegenerative diseases
  申请人：NOVARTIS FORSCHUNGSSTIFTUNG, ZWEIGNIEDERLASSUNG, FRIEDRICH MIESCHER INSTITUTE

  公开号：US20140314787A1

  公开（公告）日：2014-10-23

  The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject a therapeutically effective amount of a modulator of said endoplasmic reticulum protein retrotranslocation machinery and/or of VCP.
• Use of Small Molecule Unfolder Protein Response Modulators to Treat Tumors With Active Sonic Hedgehog (SSH) Signaling Due To Smoothened (SMO) Mutation
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US20150320723A1

  公开（公告）日：2015-11-12

  The present invention relates to methods for treating tumors having SMO mutations as well as diagnosing tumors with SMO mutations. The invention relates to methods for the treatment of cancer with ER stress-inducing compounds or UPR inducing compounds. The ER stress-inducing compounds or UPR inducing compounds might fill a clinical need for additional methods of targeting the Hh pathway, either in frontline combination therapy or in salvage therapy for relapsed patients who develop resistance to the available SMO inhibitor and offer a significant advantage over SMO-specific small molecules. Because ER stress modulators and UPR inducing compounds exploit a cellular process that is distinct from the Hh signaling pathway, their efficacy should be unaltered by acquired SMO mutation.
• [EN] NEW TREATMENT FOR NEURODEGENERATIVE DISEASES<br/>[FR] TRAITEMENT INÉDIT CONTRE LES MALADIES NEURODÉGÉNÉRATIVES
  申请人：NOVARTIS FORSCHUNGSSTIFTUNG

  公开号：WO2013068431A1

  公开（公告）日：2013-05-16

  The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject a therapeutically effective amount of a modulator of said endoplasmic reticulum protein retrotranslocation machinery and/or of VCP.